Real-world clinical remission of severe asthma with benralizumab in Spanish adults with severe asthma.

Objective: Patients with severe eosinophilic asthma experience high risk of exacerbations and reduced quality of life. Benralizumab, a monoclonal antibody binding to IL-5 receptor α subunit, is an approved drug for its treatment. The objective was to describe clinical remission after benralizumab prescription in routine clinical practice.

Effectiveness and pharmacoeconomic analysis of the treatment of severe asthma with omalizumab in clinical practice.

Objective: To assess socio-sanitary expenditure after the addition of omalizumab to standard treatment in the control of severe asthma and to analyse its effectiveness under standard clinical practice.

Method: Observational retrospective multicentre study conducted in 12  pneumology services in the Valencian Community, Spain. Data from 186  patients were analysed.